Event overview and why Establishment Labs Holdings (ESTA) is on investors’ radar

Establishment Labs Holdings (NasdaqCM:ESTA) has drawn attention after recent trading, with the stock closing at US$70.69 and showing mixed performance over the past week, month, past 3 months, and year to date.

For context, the company focuses on medical devices for breast aesthetic and reconstructive plastic surgeries. It reported revenue of US$229.576 million and a net loss of US$43.736 million, with a market value of about US$2.08b.

While the share price has eased in the very short term, with a 1 day move down 3.14% and a 90 day share price return down 7.10%, the 1 year total shareholder return of 105.37% points to strong longer term momentum. This contrasts with a more modest 3 year total shareholder return of 6.40% and a 5 year total shareholder return down 6.53%, suggesting recent optimism has shifted perceptions of both growth prospects and risk around the current US$70.69 level.

If you are comparing ESTA with other healthcare related growth stories, it can help to scan a wider set of medical and biotech plays using our healthcare focused AI stock screener, starting with 39 healthcare AI stocks.

With revenue of US$229.576 million, an ongoing net loss and a market value around US$2.08b, the key question now is whether ESTA’s sharp 1 year run has left upside on the table, or if the market is already pricing in future growth.

Most Popular Narrative: 7% Undervalued

Compared with the last close at $70.69, the most followed narrative points to a fair value of $76, suggesting some remaining upside in the current setup.

Heavy, ongoing investment in clinical trials, commercial expansion, inventory buildout, and innovation pipelines may result in costs consistently outpacing gross profit improvements, thereby potentially delaying or eroding the anticipated transition to sustainable profitability and positive cash flow.

Want to understand why this valuation still leans positive despite that cost pressure? The narrative leans on rapid revenue expansion, rising margins, and a rich future earnings multiple to justify that $76 fair value. The tension between those bullish inputs and execution risk is what really matters here.

Result: Fair Value of $76 (UNDERVALUED)

However, there are still clear risks, including potential shifts in cosmetic surgery demand and rising regulatory or environmental scrutiny on implants that could challenge this upbeat narrative.

Another way to look at ESTA’s valuation

The narrative backed by analyst targets suggests ESTA is undervalued around $70.69, with a fair value of $76 based on future earnings assumptions. The SWS DCF model, however, points to a value of $50.52, which would make the stock look expensive instead of cheap. That kind of gap raises the question of which set of assumptions you trust more.

Next Steps

With the story pulling in different directions, this is a moment to move quickly, study the data for yourself, and weigh up the stock’s mix of 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If ESTA has caught your attention, do not stop here. Broader opportunities often show up where fundamentals, income potential, and resilience quietly line up for patient investors.

• Spot potential bargains early by scanning companies that currently screen as 46 high quality undervalued stocks before the crowd fully catches on.
• Strengthen your income stream by reviewing stocks filtered as 10 dividend fortresses and see which yields might fit your goals.
• Sleep a little easier by focusing on companies identified as 63 resilient stocks with low risk scores and see which ones match your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.